The non-receptor Src tyrosine kinase is known to cooperate with the epidermal growth factor receptor in a mechanism leading to invasion and metastasis of solid tumours. With the purpose of developing agents targeted to both epidermal growth factor receptor and Src or related kinases, we embarked on the design of chimeric molecules termed combi-molecules capable of blocking both Src and epidermal growth factor receptor. To this end, we have chosen to design molecules containing a quinazoline moiety (directed at epidermal growth factor receptor) and a 7-phenyl-pyrazolopyrimidine (directed at Src). Molecular modelling showed that the optimal position to attach the linker was the 6-position of the quinazoline and the 9-position of the pyrazolopyrimidine. This has led to the synthesis of SB162, SB166 and SB163. SB163 containing the longest linker was the only molecule capable of inducing a dose-dependent inhibition of both Src and epidermal growth factor receptor. SB163 also induced a dose inhibition of Abl and PDGFR.
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Key words: drug design, mechanism-based drug design, structurebased drug The altered protein expression and activity of receptor tyrosine kinases (TK) are implicated in the progression of various types of cancers. One such dysfunction is the over-expression of the epidermal growth factor receptor (EGFR) that correlates with aggressive tumour progression and poor prognosis (1) . The c-Src non-receptor tyrosine kinase is over-expressed and activated in a large number of human malignancies and has been strongly linked to the development of cancer and progression to distant metastases (2, 3) . The disordered expression of EGFR and c-Src enhances the invasive and metastatic potential of advanced breast carcinomas (2) (3) (4) (5) (6) (7) (8) . Thus, we surmised that the design of molecules termed 'combi-molecules' with EGFR and Src inhibitory activity may lead to multitargeted drugs with enhanced ability to block tumour progression. Because of target heterogeneity in solid tumours at the advanced stages, the development of compounds with multitargeting properties has become an urgent need in cancer treatment research. To investigate the feasibility of novel dual EGFR ⁄ Src inhibitors, a molecular modelling study was undertaken using the X-ray structures of known EGFR ⁄ Src inhibitors. The first designed molecule 1 ( Figure 1 ) involved a linker attached to the 6-position of the quinazoline pharmacophore directed at EGFR and to the N1 of the purine moiety (directed at Src). Structure 1 was modelled in an attempt to predict the required position of attachment of the linker for optimal binding to the ATP site of the receptors.
The phenylamino-quinazoline group is a well-known EGFR binder, and there exists at least one experimental X-ray structure of this moiety in the EGFR active site (PDB code 1M17) (9) . The phenylamino-quinazoline group also binds to Src, and an X-ray crystal structure of Src complexed with a phenylamino-quinazoline inhibitor also exists (PDB code 2H8H) (10) . The purine moiety straddles known optimized Scr inhibitor, with at least five experimental X-ray structures of Scr complexed with purine-based inhibitors (PDB codes 1YOM, 1YOL (10), 1QCF (11), 2BDF, 2BDJ (12) . In three of these structures (1YOM, 2BDF and 2BDJ), the purine moieties bind in very similar modes, while the 1YOL and 1QCF structure reveals a different possible orientation for the purine group. These two binding modes were used to predict the potency of the designed structures. Here we describe the molecular modelling approach that led to exclusion of 1 as a possible mixed targeted structure and rationalize the design of chimeric structures SB162, SB163 and SB166 as potential mixed EGFR-Src-targeted combi-molecules ( Figure 6 ). The general steps toward the synthesis of the latter combi-molecules are also discussed.
Materials and Methods

Molecular modelling
Experimental crystal structures of a sample EGFR PDB complex (PDB code 1M17) and a number of Src complexes (PDB codes 2H8H, 1YOM, 1YOL, 1QCF, 2BDF, 2BDJ) were downloaded from the PDB. All the molecular modelling and protein alignments were performed using the MOE 2007.08 1 software package. The EGFR structure was used as a template for molecular modelling studies of quinazoline binding to the EGRF TK domain. The molecular modelling studies employed the MFF94x forcefield. All ligand geometry optimizations were carried out in the field of the fixed protein, using an RSM gradient of 0.1 kcal ⁄ mol as the termination criterion. The van der Waals interaction surfaces drawn around the binding pockets were computed using the Surfaces and Maps application in MOE. The Src protein alignments were performed with MOE pro_Align tool, using the BLOSUM62 similarity matrix. All 2D ligand interaction diagrams were produced using the MOE software. 
Enzyme assay
The EGFR kinase assay is an adaptation of methods described by Brahimi et al. (13) . Briefly, Nunc Maxisorp 96-well plates were incubated overnight at 37°C with poly(L-glutamic acid-L-tyrosine, 4:1) (PGT) in phosphate-buffered saline. The kinase reaction was performed by using 7 ng ⁄ well EGFR affinity-purified from A431 
Results and Discussion
Purine Mode I binding: X-ray structures Scr: 1YOM, 2BDF, 2BDJ The purine moiety having the most variability in Src binding mode, it was the first group considered in the study. As mentioned, there is experimental evidence of the purine moiety adopting two different orientations in the Src pocket. Examination of the H-bond contacts between the MODE I ligands and the Src receptor show that all these ligands form H-bonds with both the backbone NH nitrogen and carbonyl oxygen of residue Met_341 (see Figure 2A ).
Closer examination of the van der Waals interaction surfaces in the protein pockets revealed that the pocket shape is similar for all MODE I bindings. Taking the latter into consideration as well as the conserved H-bonds interaction with Met_341, this allowed us to propose a general SAR for MODE I binding of purine derivatives to Src (see Figure 2B ).
Purine Mode II binding: X-ray structures Scr: (1 YOL, 1QCF) A similar analysis as for MODE I was performed for MODE II binding using X-ray structures (1 YOL, 1QCF) and examination of Hbonding revealed that all these ligands form H-bonds with both backbone NH nitrogen of Met_341. H-bonds formed with Glu_339 and with the side chain of Thr_338 were also discovered (see Figure 3A) .
Consideration of the conserved H-bonds and the similarity of the Src pocket interaction surfaces allows us to propose a general SAR for MODE II binding of purine derivatives to Src (see Figure 3B ). This has then allowed us to compare the MODE I and MODE II SAR and determine which one is more suited for the design of our dual inhibitor.
Following the generation of binding MODE I and II, we were able to superpose both structures in the receptor pocket and identify potential binding affinity problems with Src. In Figure 4 , the purine ring of (1) is aligned with a 2D schematic of the purine ring orientation in binding MODE I. From Figure 4 , it is clear that the p-chlorophenyl group would hinder a MODE I orientation of compound 1 because this group would collide with the Src protein backbone in the vicinity of Met_341. In addition, the p-chlorophenyl substituent Novel strategy for the design of multitargeted drugs occupies a position on the purine ring that should contain an acceptor atom for H-bonding the peptide NH group of Met_341.
Using the same technique, in Figure 5 , the purine ring of (1) was aligned with a 2D schematic of the purine ring orientation in binding MODE II. The drawing in Figure 5 suggests that in a binding MODE II orientation, the linker group ⁄ quinazoline ring (X) of compound 1 would undergo great steric clash with the Src pocket. In MODE II binding, the exocyclic amino group points towards the wall of the Src pocket, and forms H-bonds with Glu_339 and Thr_338. Compound 1 would hardly adopt this binding mode because the linker ⁄ quinazoline group (X) would clash with the pocket. Furthermore, there is one less hydrogen available to H-bond with Glu_339 or Thr_338.
The results predicted that modification of PP2 on the aminopurine moiety would dramatically affect tyrosine kinase activity. The 9-position, which is oriented at the entrance of the binding cleft, appeared as a favourable position for structural modification. To challenge this model, we first synthesized SB75 with an acetoxyethyl group appended to the 9-position. This structure showed a dosedependent inhibition of Src (0.9 lM). These results suggest that the 9-position is suitable for placing a linker between PP2 and an EGFR inhibitor. On the other hand, quinazolines are known to be tolerant of bulky substituents at their 6-position. Thus, we used quinazolines with linkers already available in our laboratory to synthesize the novel potential dual inhibitors of Src and EGFR: SB162, SB163 and SB166 as depicted in Figure 6 .
Chemical synthesis
The synthesis of the chimeric molecules proceeded according to Schemes 1,2 and 3. It can be summarized into the coupling of the bromoethyl analogue of PP2 5 (Scheme 1) with the corresponding amine. This is exemplified in Scheme 3 wherein 5 is coupled with ethylene diamine 8 and the synthesis of SB162 and SB166 proceeded in a similar manner, using the corresponding amine-linked quinazolines. Bromo compound 5 was obtained by the bromination of alcohol 3 prepared according to an adaptation of strategy developed for the synthesis of PP2 (14) . Structure 8 was developed according to procedure developed by Domarkas (15) (see Scheme 2). The structure of SB162 and SB163, SB166 were confirmed by proton NMR and MS.
Correlation between molecular modelling predictions and the EGFR-Src tyrosine kinase inhibitory potency Modelling studies were performed on the following potential dual inhibitors of Src and EGFR, SB162 and SB163 in order to predict activity differences between the structures. SB162 contains a shorter linker than the one used in SB163. The quinazoline-based fragments of SB162 and SB163 were modelled in the EGFR pocket (1M17 PDB structure) using the PDB quinazoline ring as a template. Initially, only the quinazoline base of each structure was modelled. The full structures SB162 and SB163 with the purine appendage were modelled based on the optimized base structures. The first test was to verify whether the linker was sufficiently large to enable an ionic ⁄ H-bond interaction with the ASP_776 residue as discussed in previous work (16) .
The 3D structures show that the linker on the quinazoline base of SB162 is too short to allow an H-bond to form between the protonatable nitrogen and the ASP_776 residue. Although the nitrogen of SB162 can come close to ASP_776 -the closest approach observed in the modelling was 3.7 . Therefore, it is not close enough for a string H-bond interaction. In contrast, the linker of SB163 is Novel strategy for the design of multitargeted drugs sufficiently long for the protonatable nitrogen to contact ASP_776 with an H-bond -the model structure (see Figure 7) shows a distance of 2.6 between the ASP oxygen and the protonatable nitrogen of SB163. Other than the ASP_776 contact, all interactions between the EGFR receptor and the quinazoline base structures are the same in both structures.
Another factor that may influence activity differences between SB162 and SB163 is the size of the pendant purine-like group. In SB162, the small linker means that the bulky purine-like ring must be accommodated close to the opening of the EGFR binding pocket. In contrast, the longer linker of SB163 means that the pendant purine group is more exposed to solvent and further out of the pocket than in the SB162 compound. Modelling both ligands in the pocket shows that SB162 can be accommodated at the mouth of the EGFR binding pocket, but the group is quite bulky and limited in terms of possible orientations. In addition, it does not form any strong or specific interactions with the receptor. In contrast, the longer linker of SB163 allows the purine pendant group to clear the EGFR binding pocket. Barché chath et al.
As predicted, the results in terms of EGFR inhibitory potency showed that SB163 is a good inhibitor of EGFR (IC 50 = 0.32 lM) and a moderate inhibitor of Src with and IC 50 of 2.9 lM compared with a 1 lM binding affinity value for the known Src inhibitor PP2 (Figure 8 ). SB163 also induced dose-dependent inhibition of Abl and PDGFR. In contrast, SB162 as predicted by molecular modelling showed no activity for EGFR and for Src, indicating that the linkage of the two pharmacophores with a short spacer annihilates their activity against both oncogenes. Similarly, SB166 with a short and more rigid linker was inactive. Thus, because of its potency against EGFR and its ability to induce a dose-dependent inhibition of EGFR, SB163 was selected for further studies and it was shown in the Boyden Chamber assay that its activity was superior to that of an equimolar combination of the EGFR inhibitor Iressa + PP2. These results and the mechanism of action of SB163 are discussed in detail elsewhere (17) .
Conclusion
Cancer progression is driven by a variety of signalling pathways that ultimately lead to drug resistance and expression of angiogenic growth factors (e.g. VEGF). These factors and signalling pathways drive the invasion and metastatic processes. It has been found that EGFR synergizes with Src in cancer progression. Therefore, molecules capable of blocking both EGFR and Src could prove effective against tumours driven by the latter oncogenes. Traditionally, multitargeted molecules are obtained serendipitously, through multiple screening methods. Currently, given the known target heterogeneity of many cancers, the trends is toward the design of multitargeted drugs (18) . Although, SB163 identified through this new design approach was a moderately potent Src inhibitory combi-molecule, this work presents a paradigm shifting drug development strategy that stresses on rational design of multikinase inhibitors of oncogenes involved in aggressive tumour progression. It opens the way to the design of molecules to which multiple kinase inhibitory potency can be imprinted in a single molecule, thereby reducing the complex pharmacotoxicology associated with multiple drug administration to that of single drugs.
